Evasive spike variants elucidate the preservation of T cell immune response to the SARS-CoV-2 omicron variant
Abstract
The Omicron variants boast the highest infectivity rates among all SARS-CoV-2 variants. Despite their lower disease severity, they can reinfect COVID-19 patients and infect vaccinated individuals as well. The high number of mutations in these variants render them resistant to antibodies that otherwise neutralize the spike protein of the original SARS-CoV-2 spike protein. Recent research has shown that despite its strong immune evasion, Omicron still induces strong T Cell responses similar to the original variant. This work investigates the molecular basis for this observation using the neural network tools NetMHCpan-4.1 and NetMHCiipan-4.0. The antigens presented through the MHC Class I and Class II pathways from all the notable SARS-CoV-2 variants were compared across numerous high frequency HLAs. All variants were observed to have equivalent T cell antigenicity. A novel positive control system was engineered in the form of spike variants that did evade T Cell responses, unlike Omicron. These evasive spike proteins were used to statistically confirm that the Omicron variants did not exhibit lower antigenicity in the MHC pathways. These results suggest that T Cell immunity mounts a strong defense against COVID-19 which is difficult for SARS-CoV-2 to overcome through mere evolution. Author summary
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SARS-CoV-2 T cell responses are expected to remain robust against Omicron
S. F. Ahmed, A. A. Quadeer, M. McKay·bioRxiv·Dec 12, 2021
- Preserved T cell reactivity to the SARS-CoV-2 Omicron variant indicates continued protection in vaccinated individuals.
L. De Marco, S. D'Orso, … G. Borsellino·bioRxiv·Dec 30, 2021
- T cell response following anti COVID-19 BNT162b2 vaccination is maintained against the SARS-CoV-2 Omicron B.1.1.529 variant of concern
H. Cohen, S. Rotem, … E. Bar-Haim·bioRxiv·Jan 19, 2022
- SARS -CoV-2 T-cell immunity to variants of concern following vaccination
K. M. E. Gallagher, M. B. Leick, … M. V. Maus·bioRxiv·May 3, 2021
- A systems approach evaluating the impact of SARS-CoV-2 variant of concern mutations on CD8+ T cell responses
P. R. Buckley, C. H.-J. Lee, … H. Koohy·bioRxiv·Oct 21, 2022
- SARS-CoV-2 vaccination induces immunological memory able to cross-recognize variants from Alpha to Omicron
A. Tarke, C. H. Coelho, … A. Sette·bioRxiv·Dec 28, 2021